The media brouhaha over potential manufacturing problems at a Mylan plant has brought out the FDA. The agency says it's a"routine" fact-finding mission, following up on news that employees at a West Virginia manufacturing facility may have violated government-mandated quality control procedures. "FDA is currently conducting fact-finding and investigating the situation," spokesman Christopher Kelly told the Pittsburgh Post-Gazette.
The FDA probe comes after the Post-Gazette obtained an internal report on problems at the plant. According to that report, employees repeatedly overrode alerts of potential problems on the production line. Though there's no proof that the overrides caused actual quality problems with the prescription drugs made at the plant--indeed, Mylan says it found no such quality issues--the report deemed the process violations "pervasive" and "very serious."
Mylan stock dropped more than 10 percent yesterday as the news broke. Meanwhile, the company is facing a WHO probe at its Matrix Laboratories subsidiary in India. WHO inspectors found "major deviations" from good manufacturing practice. The company corrected some of the problems, WHO said, but other issues remain.